[1]王玲,吴秋枫△.灯盏乙素对糖尿病肾病大鼠的保护作用[J].西部中医药,2018,31(09):30-33.
 WANG Ling,WU Qiufeng.Safety Action of Scutellarin on the Rats with Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2018,31(09):30-33.
点击复制

灯盏乙素对糖尿病肾病大鼠的保护作用()
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
31
期数:
2018年09期
页码:
30-33
栏目:
出版日期:
2018-09-15

文章信息/Info

Title:
Safety Action of Scutellarin on the Rats with Diabetic Nephropathy
文章编号:
1004-6852(2018)09-0030-04
作者:
王玲吴秋枫△
武汉科技大学附属天佑医院中医科,湖北 武汉 430064
Author(s):
WANG Ling, WU Qiufeng△
TCM Department, Tianyou Hospital Affiliated to Wuhan University of Science & Technology, Wuhan 430064, China
关键词:
糖尿病肾病肾脏核转录因子E2相关因子2血红素加氧酶1灯盏乙素
Keywords:
diabetic nephropathy kidney nuclear factor E2 related factor 2 heme oxygenase-1 scutellarin
分类号:
R285.5
文献标志码:
A
摘要:
目的:探讨灯盏乙素(SC)对糖尿病肾病(DN)大鼠的保护作用及其分子机制。方法:将雄性SD大鼠50只随机分为5组各10只,正常对照组给予普通饲料喂养,DN模型组以及SC低剂量[25 mg/(kg·d)]组、中剂量[50 mg/(kg·d))组以及高剂量[100 mg/(kg·d)]组给予高脂饲料喂养,4周后进行链脲佐菌素( STZ,60 mg/kg)注射造模,造模成功后SC各剂量组灌胃SC,DN模型组灌胃相同体积生理盐水,4周后处死大鼠,收集血清和肾脏组织进行相关因子检测。结果:与正常对照组比较,DN模型组大鼠血清中血尿素氮(BUN)、血肌酐(Scr)、葡萄糖、胰岛素、胰岛素抵抗指数(HOMA-IR)、丙二醛(MDA)、甘油三酯(TG)、总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)含量升高(P<0.05),SC治疗后各指标下降(P<0.05),且具有剂量依赖性;抗氧化因子超氧化物歧化酶(SOD)和谷胱甘肽(GSH)含量以及核转录因子E2相关因子2(Nrf2)和血红素加氧酶1(HO-1)的mRNA和蛋白表达水平在DN模型组中降低,经SC治疗后下降明显(P<0.05),且具有剂量依赖性。结论:SC可改善DN大鼠肾功能、降低体内IR与脂质沉积,通过调节 Nrf2 /HO-1信号通路减轻氧化应激反应从而缓解DN。
Abstract:
Objective: To investigate the safety action of scutellarin (SC) on the rats with diabetic nephropathy (DN) and its molecular mechanism. Methods: Fifty rats were randomly allocated to five groups, ten rats each group, normal control group was fed with ordinary feed, DN model group, low, moderate and high doses groups of SC [25, 50 and 100 mg/(kg·d)] were given high fat feed, the rats were established by injecting streptozotocin (STZ) in four weeks, different dose groups of SC were drenched with SC after successfully modeling, DN model group accepted gastric lavage of physiological saline in the same volume, the rats were sacrificed in four weeks, the related factors were detected in the serum and renal tissue. Results: Compared with normal control group, the contents of BUN, Scr, glucose, insulin, HOMA-IR, MDA, TG, TC and LDL-C evaluated in the rats of DN model group (P<0.05), different indexes lowered after treated by SC(P<0.05), in dose-dependent manner; the contents of SOD, GSH, the levels of Nrf2/HO-1 mRNA and protein expressions lowered in DN model group, they decreased obviously after treated by SC(P<0.05), in dose-dependent manner. Conclusion: SC could improve renal function of DN rats, decrease IR and lipidosis, and alleviate DN by regulating Nrf2/HO-1 signal channel and lightening oxidative stress reaction.

相似文献/References:

[1]林晓芬,黄燕璇.益肾汤联合厄贝沙坦及胰激肽原酶治疗早期糖尿病肾病的疗效观察[J].西部中医药,2013,26(07):68.
 LIN Xiaofen,HUANG Yanxuan.Clinical Observation on YiShenTang Combined with Irbesartan and Pancreatic Kininogenase in the Treatment for Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(09):68.
[2]王学琦,李丰华,张荣华,等.温肾汤治疗早期糖尿病肾病80例[J].西部中医药,2013,26(09):62.
 WANG Xueqi,LI Fenghua,ZHANG Ronghua,et al.WenShenTang for 80 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(09):62.
[3]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病有效性及安全性的系统评价[J].西部中医药,2014,27(01):77.
 REN Fang,XU Houqian.Systematic Review of the Effectiveness and Safety of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(09):77.
[4]丁夏楠,许筠△,苏建平,等.益肾逐瘀方治疗糖尿病肾病蛋白尿37例[J].西部中医药,2014,27(04):96.
 DING Xianan,XU Jun,SU Jianping,et al.Treatment for Proteinuria of 37 Patients with Diabetic Nephropathy by Kidney-invigorating Stagnation-dispelling Prescription[J].Western Journal of Traditional Chinese Medicine,2014,27(09):96.
[5]肖远莉.循证护理的优效性及影响因素分析———来自终末期糖尿病肾病患者血液透析的证据[J].西部中医药,2014,27(08):127.
[6]刘涛.缬沙坦联合复方丹参滴丸对早期2型糖尿病肾病患者尿微量白蛋白的影响[J].西部中医药,2015,28(05):106.
[7]连琯,史晓伟.当归补血汤合金水宝治疗早期糖尿病肾病16例临床观察[J].西部中医药,2013,26(06):68.
 LIAN Guan,SHI Xiaowei.Clinical Observation on DangGui BuXueTang and JinShuiBao in Treating 16 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(09):68.
[8]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病随机对照试验报告质量评价[J].西部中医药,2013,26(12):1.
 REN Fang,XU Houqian.Quality Evaluation of the Report for Randomized Controlled Trials of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(09):1.
[9]朱苗蕊,指导:金智生.糖脂平治疗早期糖尿病肾病60例疗效观察*[J].西部中医药,2013,26(03):74.
 ZHU Miaorui,Director: JIN Zhisheng.Clinical Observation on TangZhiPing in Treating 60 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(09):74.
[10]马天寿.血塞通联合西药治疗糖尿病肾病80例[J].西部中医药,2013,26(08):96.
 MA Tianshou.XueSaiTong Injection and Western Medicine in Treating 80 Cases of Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(09):96.

备注/Memo

备注/Memo:
收稿日期:2017-05-04 *基金项目:湖北省自然科学基金项目(编号2015CFC187)。 作者简介:王玲(1982—),女,主治医师。研究方向:糖尿病的基础医学研究。 △通讯作者:吴秋枫(1966—),女,主任医师。研究方向:糖尿病的基础医学研究。
更新日期/Last Update: 2018-09-15